Elevated levels of cerebrospinal fluid guanosine 3′,5′-cyclic monophosphate (C-GMP) in systemic lupus erythematosus

Abstract

Cerebrospinal fluid samples from patients with systemic lupus erythematosus (SLE) and neurologic involvement were evaluated for guanosine 3′,5′-cyclic monophosphate (C-GMP) and cyclic adenosine monophosphate (C-AMP) content by radioimmunoassay and radioassay, respectively. Twenty-five samples from 15 patients with SLE had an average C-GMP level of 2.4 nM ± 0.44 (average ± SE) compared with 0.68 nM ± 0.14 in a control group with lumbosacral pain (p < 0.0002). No significant difference was noted in C-AMP content between patients with SLE and control subjects. C-GMP levels in Cerebrospinal fluid samples from patients with SLE who had changing neurologic disease were higher than in those with stable neurologic disease. Elevated C-GMP levels in Cerebrospinal fluid correlated with the leukocyte number in Cerebrospinal fluid (r = 0.53, p < 0.01), but not with the initial pressure, protein concentration or daily prednisone dosage. Experimental results suggested that leukocytes in the Cerebrospinal fluid were not the source of elevated C-GMP levels. Thus, elevated C-GMP levels in cerebrospinal fluid of patients with SLE appeared to reflect neurologic involvement. C-GMP levels were also found to be elevated in five patients with other active neurologic diseases; thus, measurement of C-GMP in Cerebrospinal fluid may have more general diagnostic value.